Company description

Akebia Therapeutics (AKBA) is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with kidney disease. Founded in 2007 and headquartered in Cambridge, Massachusetts, AKBA is focused on addressing the unmet needs of patients with chronic kidney disease (CKD), anemia, and rare kidney disorders. The company's lead product candidate, vadadustat, is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) currently in global Phase 3 clinical trials for the treatment of anemia due to CKD. AKBA's mission is to improve the lives of millions of people around the world suffering from kidney disease by providing them with safe and effective treatments. With a dedicated team of scientists, researchers, and collaborators, AKBA is committed to making a difference in the lives of patients and becoming a leader in the field of renal therapeutics. The company's innovative approach to treating kidney disease has the potential to transform the standard of care and improve outcomes for patients. As a publicly traded company, AKBA is well-positioned to continue advancing its pipeline of promising therapies and bringing hope to those affected by kidney disease.